Comparative Pharmacology
Head-to-head clinical analysis: EMBEDA versus ULTRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMBEDA versus ULTRAM.
EMBEDA vs ULTRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMBEDA is a combination of morphine sulfate, a full opioid agonist, and naltrexone hydrochloride, an opioid antagonist. Morphine binds to mu-opioid receptors in the CNS, altering pain perception and response. Naltrexone is sequestered in the core and is released if the pellets are crushed or chewed, potentially precipitating withdrawal or blockade of morphine effects.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
1 to 2 capsules orally every 12 hours, titrated to pain relief. Maximum daily dose: 100 mg naltrexone (equivalent to 100 mg morphine). Capsules must be swallowed whole.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
None Documented
None Documented
Morphine: 2-4 hours; naltrexone: 4-13 hours (active metabolite 6β-naltrexol: 12-18 hours). Clinically, morphine's half-life is prolonged in hepatic or renal impairment.
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
Renal: ~60% (morphine), ~20% (naltrexone, in urine as unchanged drug and metabolites); biliary/fecal: ~10% (morphine-3-glucuronide and other metabolites).
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic